Clinical guidelines for diagnosis and treatment of prolactinoma and hyperprolactinemia;Guía clínica de diagnóstico y tratamiento del prolactinoma y la hiperprolactinemia

Endocrinologia y Nutricion

Volumn 60, Issue 6, 2013, Pages 308-319

  Halperin Rabinovich, Irene ^a   Cámara Gómez, Rosa ^b   García Mouriz, Marta ^c   Ollero García Agulló, Dolores ^c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c Instituto de Investigación Sanitaria de Navarra   (Spain)

Author keywords

Clinical guidelines; Hyperprolactinemia; Prolactinoma

Indexed keywords

ARTICLE; DIFFERENTIAL DIAGNOSIS; EVIDENCE BASED PRACTICE; HUMAN; HYPERPROLACTINEMIA; PRACTICE GUIDELINE; PROLACTINOMA; SYSTEMATIC REVIEW;

ALGORITHMS; HUMANS; HYPERPROLACTINEMIA; PITUITARY NEOPLASMS; PROLACTINOMA;

EID: 84879607352     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/j.endonu.2012.11.005     Document Type: Article

References (52)

1. Klibanski A. Prolactinomas. N Engl J Med 2010, 362:1219-1226.
2. Fajardo-Montañana C., Daly Adrian F., Riesgo-Suárez P., Gómez-Vela J., Tichomirowa M.A., Cámara-Gómez R., et al. Mutaciones de AIP en adenomas hipofisarios familiares y esporádicos: experiencia local y revisión de la literatura. Endocrinol Nutr 2009, 56:369-377.
3. Melmed S., Casanueva F.F., Hoffman A.R., Kleinberg D.L., Montori V.M., Schlechte J.A., et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011, 96:273-288.
4. Casanueva F., Molitch M., Schlechte J., Abs R., Bonert V., Bronstein M.D., et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006, 65:265-273.
5. Moreno B., Obiols G., Páramo C., Zugasti A. Guía clínica del manejo del prolactinoma y otros estados de hiperprolactinemia. Endocrinol Nutr 2005, 52:9-17.
6. Petakov M.S., Damjanovia S.S., Nikolia-Durovia M.M., Dragojlovia Z.L., Obradovia S., Gligorovia M.S., et al. Pituitary adenomas secreting large amounts of prolactin may give false low values in inmunoradiometric assays. The hook effect. J Endocrinol Invest 1998, 21:184-188.
7. McKenna T.J. Should macroprolactin be measured in all hyperprolactinaemic sera?. Clin Endocrinol (Oxf) 2009, 71:466-469.
8. Gibney J., Smith T.P., Mac Kenn T.J. The impact on clinical practice of routine screening for macroprolactin. J Clin Endocrinol Metab 2005, 90:3927-3932.
9. Molitch M.E. Medication-induced hyperprolactinemia. Mayo Clin Proc 2005, 80:1050.
10. Famini P., Maya M.M., Melmed S. Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients. J Clin Endocrinol Metab 2011, 96:1633-1641.
11. Ikeda H., Abe T., Watanaba K. Usefulness of composite methionine-positron emission tomography/3.0-tesla magnetic resonance imaging to detect the localization and extent of early-stage Cushing adenoma. J Neurosurg 2010, 112:750-755.
12. Ginovart N., Galineau L., Willeit M., Mizrahi R., Bloomfield P.M. Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J Neurochem 2006, 97:1089-1103.
13. Elston M.S., McDonald K.L., Clifton-Bligh R.J., Robinson B.G. Familial pituitary tumor syndromes. Nat Rev Endocrinol 2009, 5:453-461.
14. Gillam M.P., Molitch M.E., Lombardi G., Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006, 27:485-534.
15. Schlechte J., Dolan K., Sherman B., Clapler F., Luciano A The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 1989, 68:412-418.
16. Webster J., Piscitelli G., Polli A., Ferrari C.I., Ismail I., Scanlon M.F. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994, 331:904-909.
17. Leong K.S., Foy P.M., Swift A.C., Atkin S.L., Hadden D.R., Mac Farlane I.A. CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas. Clin Endocrinol (Oxf) 2000, 52:43-49.
18. Iyer P., Molitch M.E. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas. Endocr Pract 2011, 17:e55-e58.
19. Ono M., Miki N., Kawamata T., Makino R., Amano K., Seki T., et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 2008, 93:4721-4727.
20. Delgrange E., Daems T., Verhelst J., Abs R., Maiter D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol 2009, 160:747-752.
21. Herring N., Szmigielski C., Becher H., Karavitaki N., Wass J.A. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf) 2009, 70:104-108.
22. Vallette S., Serri K., Rivera J., Santagata P., Delorme S., Garfield N., et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 2009, 12:153-157.
23. Wakil A., Rigby A.S., Clark A.L., Kallvikbacka-Bennett A., Atkin S.L. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 2008, 159:11-14.
24. Valassi E., Klibanski A., Biller B.M.K. Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab 2010, 95:1025-1033.
25. Klibanski A. Dopamine agonist therapy in prolactinomas: when can treatment be discontinued. J Clin Endocrinol Metab 2009, 94:2247-2249.
26. Barber T.M., Kenkre J., Garnett C., Scott R.V., Byrne J.V., Wass J.A.H. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy with prolactinoma occurs commonly specially in macroprolactinoma. Clin Endocrinol (Oxf) 2011, 75:819-824.
27. Ciccarelli E., Grottoli S., Razzore P., Gaia D., Bertagna A., Cirillo S., et al. Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumourous hyperprolactinaemia and outcome of drug-induced pregnancy. J Endocrinol Invest 1997, 20:547-551.
28. Barker F.G., Klibanski A., Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 2003, 88:4709-4719.
29. Landolt A.M. Surgical treatment of pituitary prolactinomas: postoperative prolactine and fertility in seventy patients. Fertil Steril 1981, 35:620-625.
30. Soule S.G., Farhi J., Conway G.S., Jacobs H.S., Powell M. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy. Clin Endocrinol (Oxf) 1996, 44:711-716.
31. Babey M., Sahli R., Vajtai I., Andres R.H., Seiler R.W. Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonist. Pituitary 2011, 14:222-230.
32. Amar A.P., Couldwell W.T., Chen J.C., Weiss M.H. Predictive value of serum prolactine levels measured immediately after transsphenoidal surgery. J Neurosurg 2002, 97:307-314.
33. Serri O., Rasio E., Beauregard H., Hardy J., Somma M. Recurrence oh hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med 1983, 309:280-283.
34. Massoud F., Serri O., Hardy J., Somma M., Beauregard H. Transsphenoidal adenomectomy for microprolactinomas: 10-20 years of follow-up. Surg Neurol 1996, 45:341-346.
35. Tanaka S., Link M.J., Brown P.D., Stafford S.L., Young W.F., Pollock B.E. Gamma knife radiosurgery for patients with prolactin-secreting pituitary adenomas. World Neurosurg 2010, 74:147-152.
36. Brada M., Ajiyhkumar T.V., Minniti C. Radiosurgery for pituitary adenomas. Clin Endocrinol (Oxf) 2004, 61:531-534.
37. De Rosa M., Colao A., di Sarno A., Ferone D., Landi M.L., Zarrilli S., et al. Cabergolina treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptin. Eur J Endocrinol 1998, 138:286-293.
38. Molitch M. Prolactinomas and pregnancy. Clin Endocrinol (Oxf) 2010, 73:147-148.
39. Bigazzi M., Ronga R., Lancranjan I., Ferraro S., Branconi F., Buzzoni P., et al. A pregnancy in an acromegalic woman during bromocriptine treatment: effects on growth hormone and prolactin in the maternal, fetal, and amniotic compartments. J Clin Endocrinol Metab 1979, 48:9-12.
40. Rigg L.A., Lein A., Yen S.S. Pattern of increase in circulating prolactin levels during human gestation. Am J Obstet Gynecol 1977, 129:454-456.
41. Gonzalez J.G., Elizondo G., Saldivar D., Nanez H., Todd L.E., Villarreal J.Z. Pituitary gland growth during normal pregnancy: in vivo study using magnetic resonance imaging. Am J Med 1988, 85:217-220.
42. Colao A., Abs R., Barcena D.G., Chanson P., Paulus W., Kleinberg D.L. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol (Oxf) 2008, 68:66-71.
43. Stalldecker G., Mallea-Gil M.S., Guitelman M., Alfieri A., Ballarino M.C., Boero L., et al. Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature. Pituitary 2010, 1:345-350.
44. Crosignani P.G., Mattei A.M., Severini V., Cavioni V., Maggioni P., Testa G. Long term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women. Eur J Obs Gyn Rep Biol 1992, 44:175-180.
45. Colao A., Loche S. Prolactinomas in children and adolescents. Endocr Dev Basel Karger 2010, 17:146-159.
46. Karunakaran S., Page R.C., Wass J.A. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 2001, 54:295-300.
47. Thapar K., Kovacs K., Scheithauer B.W., Stefaneanu L., Horvath E., Pernicone P.J., et al. Proliferaty activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 2004, 61:111-116.
48. Katsas G.A., Nomikos P., Kpntogeorgos G., Buchfelder M., Grooman A.B. Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 2005, 90:3089-3099.
49. Lim S., Shahinian H., Maya M.M., Yong W., Heaney A.P. Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol 2006, 7:518-520.
50. McCormack A.I., McDonald K.L., Gill A.J., Clark S.J., Burt M.G., Campbell K.A., et al. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf) 2009, 71:226-233.
51. Luque G.M., Pérez-Millán M.I., Ornstein A.M., Cristina C., Becu-Villalobos D. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas. J Pharmacol Exp Ther 2011, 337:766-774.
52. Lau Q., Scheithauer B., Kovacs K., Horvath E., Syro L.V., Lloyd R. MGMT immunoexpression in aggressive pituitary adenoma and carcinoma. Pituitary 2010, 13:367-379.